MarketVIEW: Parkinson's disease vaccines (CAT: VAMV049)

Product Name: MarketVIEW: Parkinson's disease vaccines
Description: Global vaccine commercial opportunity assessment
Contents: Executive presentation + 1 forecast model
Therapeutic Area: Novel vaccines
Publication date: February 2015
Catalogue No: VAMV049

Background

Parkinson’s disease is a degenerative disorder of the central nervous system where main symptoms are tremor at rest, stiffness, slowing of movement and postural instability. It is estimated that 6.3 million people have Parkinson’s worldwide, affecting all races and cultures. After Alzheimer’s, it is the second most prevalent neurodegenerative disorder, affecting 1% of those over 60, and 4% of those over 80. Parkinson’s disease is associated with a substantial economic burden estimated $14 bn in the US, 2010.

There is currently no cure for Parkinson’s disease and treatments are concentrated on the management of symptoms. The concept of a therapeutic vaccine acting against alpha-synuclein has prompted biotech AFFiRiS AG to investigate a first in class vaccine (PD01A) currently in Phase I clinical testing. AFFiRiS are part of a new EU consortium SYMPATH which is also progressing another candidate PD03A also based on the technology (AFFITOPE®)

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the current and potential market for Parkinson’s disease vaccine(s) using a patient based value/volume forecast for major Western markets to 2030. The forecast gives revenues and volume shares for Western competitors in 3 uptake scenarios >40 yrs. The analysis also takes into account the possibility of prophylatic use and provides an up-to-date review on all aspects of disease epidemiology, treatment and patient management.
Methodology

_VacZine Analytics_ has closely monitored all significant source material pertaining to Parkinson’s disease. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by _VacZine Analytics_ in field of novel vaccines has also been utilised. ***See Bibliography for exact sources.***

**PRODUCT CONTENTS:**

_Published February 2014 (CAT No: VAMV049)_

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

- Authors Note
- Executive summary
- Commercial model: key outputs
- Parkinson's disease vaccine: total available market ($m) to 2030
- Parkinson's disease vaccine: predicted global demand (doses 000)
- Parkinson's disease vaccine: available global market per country ($m) to 2030
- Parkinson's disease vaccine: available US market ($m) to 2030
- Parkinson's disease vaccine: treated compliant patients to 2030 (US)
- Parkinson's disease: brief disease background
- Parkinson's disease: causes
- Parkinson's disease: symptoms
- Parkinson's disease: global epidemiology
- Parkinson's disease: US epidemiology
- Parkinson's disease: European epidemiology
- Parkinson's disease: diagnosis
- Parkinson's disease: diagnosis (UK)
- Parkinson's disease: treatment overview
- Parkinson's disease: treatment options
- Parkinson's disease: effectiveness of treatment
- Parkinson's disease: cost of treatment
- Parkinson's disease: financial impact of the disease
- Parkinson's disease: financial impact of the disease in the US
- Parkinson's disease: financial impact of the disease in the UK
- Parkinson's disease: future impact
- Parkinson's disease vaccine: development status to date
- The role of a Parkinson's disease vaccine
- Therapeutic vaccination for Parkinson’s disease
- Repositioning the BCG vaccine
- AFFiRiS PD01A: development status
- SYMPATH members
- SYMPATH: EU-Team Launches Clinical Trial
Continued..........

Addressable vaccine populations
Parkinson's disease vaccine forecast model: assumptions
Parkinson's disease vaccine: target product profile
Forecast vaccine population flow
Commercial model assumptions (base case)
Commercial model assumptions (high and low case)
Commercial model assumptions by country (base case)
Commercial model assumptions by country (low case)
Commercial model assumptions by country (high case)
Bibliography
Disclaimer
About VacZine Analytics

PAGES: 67 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS VALUE - high
CHARTS VALUE - base
CHARTS VALUE - low
CHARTS VOLUME - high
CHARTS VOLUME - base
CHARTS VOLUME - low
Global volume summary
Global value summary
US (high)
Canada (high)
United Kingdom (high)
France (high)
Germany (high)
Italy (high)
Spain (high)
Australia (high)
Japan (high)
US (base)
Canada (base)
United Kingdom (base)
France (base)
Germany (base)
Italy (base)
Spain (base)
Australia (base)
Japan (base)
US (low)
Canada (low)
United Kingdom (low)
France (low)
Germany (low)
Italy (low)
Spain (low)
Australia (low)
Japan (low)
Assumptions
Backpage

WORKSHEETS: ~84
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $7995.00/ GBP £5330.00 (Region license)*
- PRESENTATION OR MODEL ONLY - USD $2665.00 (Region license)*

*Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY:

67. Schneeberger et al. (2011) Vaccination for Parkinson’s disease. Parkinsonism and Related Disorders 18S1 S11–S13
69. Schneeberger et al. (2011) Vaccination for Parkinson’s disease. Parkinsonism and Related Disorders 18S1 S11–S13
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy: The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency located in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009

Follow us on Twitter @vaczineanalytic


Signup to our free vaccine pipeline datalow - http://www.vaccinestats.com